1 Min Read
Dec 9 (Reuters) - Astrazeneca Plc :
* US FDA has accepted first biologics license application for durvalumab
* US FDA granted priority review status with a prescription drug user fee act (PDUFA) set for Q2 of 2017.
* Currently has more than 30 ongoing durvalumab clinical trials in combination with other io agents and targeted therapies. Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)